The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Jiangsu Nhwa Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.96% CNY25.50
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 25 694 mill |
| EPS: | 1.060 |
| P/E: | 24.06 |
| Earnings Date: | Jul 31, 2024 |
| SharesOutstanding: | 1 007.59 mill |
| Avg Daily Volume: | 11.01 mill |
| RATING 2024-05-06 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.67x |
| Company: PE 24.06 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.53x |
| Company: PE 24.06 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY44.18 (73.24%) CNY18.68 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 24.44 - 26.36 ( +/- 3.78%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY25.50 (1.96% ) |
| Volume | 8.66 mill |
| Avg. Vol. | 11.01 mill |
| % of Avg. Vol | 78.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002262.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002262.SZ
Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.